| Rx0000191 |
Jaguar Health |
06/30/2020 |
70564080260 |
Mytesi |
04/09/2020 |
1537.60 |
2206.12 |
None |
Single Source Drug |
None |
1 |
None |
1 |
No changes. |
None |
09/25/2017 |
Glenmark Pharmaceuticals Ltd |
None |
1 |
https://www.businesswire.com/news/home/20170925005703/en/Jaguar-Subsidiary-Napo-Pharmaceuticals-Glenmark-Pharmaceuticals-Sign |
652.21 |
540.00 |
2012 |
540.00 |
None |
None |
| Rx0000016 |
Janssen |
03/31/2020 |
50458058501 |
CONCERTA® Strength:18 mg. Package Size:100 Form:Tablet |
01/20/2020 |
23.17 |
1181.87 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458058801 |
CONCERTA® Strength:27 mg. Package Size:100 Form:Tablet |
01/20/2020 |
23.75 |
1211.49 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458058601 |
CONCERTA® Strength:36 mg. Package Size:100 Form:Tablet |
01/20/2020 |
24.50 |
1249.70 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458058701 |
CONCERTA® Strength:54 mg. Package Size:100 Form:Tablet |
01/20/2020 |
26.66 |
1359.85 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
59676027801 |
EDURANTTM Strength:25 MG Package Size:30 Form:Tablet |
01/20/2020 |
50.18 |
1165.29 |
04/21/2025 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
59676057001 |
INTELENCE® Strength:100 MG Package Size:120 Form:Tablet |
01/20/2020 |
27.14 |
1383.82 |
06/13/2021 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020 and includes 6 months of pediatric exclusivity. |
| Rx0000016 |
Janssen |
03/31/2020 |
59676057101 |
INTELENCE® Strength:200 MG Package Size:60 Form:Tablet |
01/20/2020 |
27.13 |
1383.82 |
06/13/2021 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020 and includes 6 months of pediatric exclusivity. |
| Rx0000016 |
Janssen |
03/31/2020 |
59676057201 |
INTELENCE® Strength:25 MG Package Size:120 Form:Tablet |
01/20/2020 |
6.78 |
345.95 |
06/13/2021 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020 and includes 6 months of pediatric exclusivity. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458055401 |
INVEGA® Strength:1.5 mg Package Size:30 Form:Extended Release Tablet |
01/20/2020 |
23.57 |
1202.15 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458055010 |
INVEGA® Strength:3 mg Package Size:100 Form:Extended Release Tablet |
01/20/2020 |
78.57 |
4007.18 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458055001 |
INVEGA® Strength:3 mg Package Size:30 Form:Extended Release Tablet |
01/20/2020 |
23.57 |
1202.15 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458055110 |
INVEGA® Strength:6 mg Package Size:100 Form:Extended Release Tablet |
01/20/2020 |
78.57 |
4007.18 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458055101 |
INVEGA® Strength:6 mg Package Size:30 Form:Extended Release Tablet |
01/20/2020 |
23.57 |
1202.15 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458055210 |
INVEGA® Strength:9 mg Package Size:100 Form:Extended Release Tablet |
01/20/2020 |
117.86 |
6010.72 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458055201 |
INVEGA® Strength:9 mg Package Size:30 Form:Extended Release Tablet |
01/20/2020 |
35.36 |
1803.22 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458056201 |
INVEGA® SUSTENNA® Strength:117 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/20/2020 |
65.52 |
1402.65 |
01/26/2031 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458056301 |
INVEGA® SUSTENNA® Strength:156 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/20/2020 |
87.36 |
1870.28 |
01/26/2031 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458056401 |
INVEGA® SUSTENNA® Strength:234 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/20/2020 |
131.04 |
2805.35 |
01/26/2031 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458056001 |
INVEGA® SUSTENNA® Strength:39 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/20/2020 |
21.84 |
467.53 |
01/26/2031 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458056101 |
INVEGA® SUSTENNA® Strength:78 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/20/2020 |
43.68 |
935.09 |
01/26/2031 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458060601 |
INVEGA® TRINZA® Strength:273 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/20/2020 |
131.04 |
2805.26 |
04/05/2036 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458060701 |
INVEGA® TRINZA® Strength:410 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/20/2020 |
196.56 |
4207.94 |
04/05/2036 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458060801 |
INVEGA® TRINZA® Strength:546 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/20/2020 |
262.09 |
5610.85 |
04/05/2036 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458060901 |
INVEGA® TRINZA® Strength:819 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/20/2020 |
393.12 |
8416.04 |
04/05/2036 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458054360 |
INVOKAMET® Strength:150/1000 MG Package Size:60 Form:Tablet |
01/20/2020 |
24.22 |
518.54 |
02/26/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458054260 |
INVOKAMET® Strength:150/500 MG Package Size:60 Form:Tablet |
01/20/2020 |
24.22 |
518.54 |
02/26/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458054160 |
INVOKAMET® Strength:50/1000 MG Package Size:60 Form:Tablet |
01/20/2020 |
24.22 |
518.54 |
02/26/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458054060 |
INVOKAMET® Strength:50/500 MG Package Size:60 Form:Tablet |
01/20/2020 |
24.22 |
518.54 |
02/26/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458094301 |
INVOKAMET® XR Strength:150/1000 MG Package Size:60 Form:Tablet |
01/20/2020 |
24.22 |
518.54 |
02/26/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458094201 |
INVOKAMET® XR Strength:150/500 MG Package Size:60 Form:Tablet |
01/20/2020 |
24.22 |
518.54 |
02/26/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458094101 |
INVOKAMET® XR Strength:50/1000 MG Package Size:60 Form:Tablet |
01/20/2020 |
24.22 |
518.54 |
02/26/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458094001 |
INVOKAMET® XR Strength:50/500 MG Package Size:60 Form:Tablet |
01/20/2020 |
24.22 |
518.54 |
02/26/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458014030 |
INVOKANA® Strength:100mg Package Size:30 Form:Tablet |
01/20/2020 |
24.22 |
518.53 |
02/26/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458014090 |
INVOKANA® Strength:100mg Package Size:90 Form:Tablet |
01/20/2020 |
72.67 |
1555.61 |
02/26/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458014130 |
INVOKANA® Strength:300mg Package Size:30 Form:Tablet |
01/20/2020 |
24.22 |
518.53 |
02/26/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458014190 |
INVOKANA® Strength:300mg Package Size:90 Form:Tablet |
01/20/2020 |
72.67 |
1555.61 |
02/26/2029 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
59676057530 |
PREZCOBIX™ (darunavir 800mg, cobicistat 150mg) Strength:800 MG/150 MG Package Size:30 Form:Tablet |
01/20/2020 |
86.91 |
2018.20 |
10/04/2032 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
59676056401 |
PREZISTA® Strength:150 MG Package Size:240 Form:Tablet |
01/20/2020 |
76.03 |
1765.73 |
06/26/2027 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020 and includes 6 months of pediatric exclusivity. |
| Rx0000016 |
Janssen |
03/31/2020 |
59676056201 |
PREZISTA® Strength:600 MG Package Size:60 Form:Tablet |
01/20/2020 |
76.03 |
1765.73 |
06/26/2027 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020 and includes 6 months of pediatric exclusivity. |
| Rx0000016 |
Janssen |
03/31/2020 |
59676056301 |
PREZISTA® Strength:75 MG Package Size:480 Form:Tablet |
01/20/2020 |
76.03 |
1765.73 |
06/26/2027 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020 and includes 6 months of pediatric exclusivity. |
| Rx0000016 |
Janssen |
03/31/2020 |
59676056630 |
PREZISTA® Strength:800 MG Package Size:30 Form:Tablet |
01/20/2020 |
76.02 |
1765.73 |
06/26/2027 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020 and includes 6 months of pediatric exclusivity. |
| Rx0000016 |
Janssen |
03/31/2020 |
59676056501 |
PREZISTA® ORAL SUSPENSION Strength:100MG/mL Package Size:200mL Form:Oral Suspension |
01/20/2020 |
42.24 |
980.90 |
06/26/2027 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020 and includes 6 months of pediatric exclusivity. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458030911 |
RISPERDAL® CONSTA® Strength:12.5 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/20/2020 |
11.87 |
254.27 |
None |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458030611 |
RISPERDAL® CONSTA® Strength:25 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/20/2020 |
23.75 |
508.50 |
11/25/2020 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020 and includes 6 months of pediatric exclusivity. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458030711 |
RISPERDAL® CONSTA® Strength:37.5 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/20/2020 |
35.63 |
762.79 |
11/25/2020 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020 and includes 6 months of pediatric exclusivity. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458030811 |
RISPERDAL® CONSTA® Strength:50 mg Package Size:1 Form:Disposable Syringe/Dose Pack |
01/20/2020 |
47.51 |
1017.07 |
11/25/2020 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020 and includes 6 months of pediatric exclusivity. |
| Rx0000016 |
Janssen |
03/31/2020 |
57894007101 |
SIMPONI® (golimumab) Prefilled Syringe Strength:100mg/1mL Package Size:1 Form:1 Single syringe |
01/20/2020 |
248.86 |
5779.26 |
02/03/2024 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. This product is not listed in the Orange Book, and the patent expiration date provided is the latest projected patent expiration date Johnson & Johnson has or otherwise intends to make publicly available. |
| Rx0000016 |
Janssen |
03/31/2020 |
57894007001 |
SIMPONI® (golimumab) Prefilled Syringe Strength:50mg/0.5mL Package Size:1 Form:1 Single syringe |
01/20/2020 |
216.41 |
5025.43 |
02/03/2024 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. This product is not listed in the Orange Book, and the patent expiration date provided is the latest projected patent expiration date Johnson & Johnson has or otherwise intends to make publicly available. |
| Rx0000016 |
Janssen |
03/31/2020 |
57894007102 |
SIMPONI® (golimumab) SmartJect® xAutoinjector Strength:100mg/1mL Package Size:1 Form:1 Single Autoinjector |
01/20/2020 |
248.86 |
5779.26 |
02/03/2024 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. This product is not listed in the Orange Book, and the patent expiration date provided is the latest projected patent expiration date Johnson & Johnson has or otherwise intends to make publicly available. |
| Rx0000016 |
Janssen |
03/31/2020 |
57894007002 |
SIMPONI® (golimumab) SmartJect® xAutoinjector Strength:50mg/0.5mL Package Size:1 Form:1 Single Autoinjector |
01/20/2020 |
216.41 |
5025.43 |
02/03/2024 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. This product is not listed in the Orange Book, and the patent expiration date provided is the latest projected patent expiration date Johnson & Johnson has or otherwise intends to make publicly available. |
| Rx0000016 |
Janssen |
03/31/2020 |
57894006003 |
STELARA® (ustekinumab) prefilled syringe Strength:45mg/0.5mL Package Size:1 Form:1 Single syringe |
01/20/2020 |
539.11 |
11541.42 |
09/25/2023 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. This product is not listed in the Orange Book, and the patent expiration date provided is the latest projected patent expiration date Johnson & Johnson has or otherwise intends to make publicly available. |
| Rx0000016 |
Janssen |
03/31/2020 |
57894006103 |
STELARA® (ustekinumab) prefilled syringe Strength:90mg/1mL Package Size:1 Form:1 Single syringe |
01/20/2020 |
1078.23 |
23082.84 |
09/25/2023 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. This product is not listed in the Orange Book, and the patent expiration date provided is the latest projected patent expiration date Johnson & Johnson has or otherwise intends to make publicly available. |
| Rx0000016 |
Janssen |
03/31/2020 |
57894006002 |
STELARA® (ustekinumab) vial Strength:45mg Package Size:1 Form:1 Single vial |
01/20/2020 |
539.11 |
11541.42 |
09/25/2023 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. This product is not listed in the Orange Book, and the patent expiration date provided is the latest projected patent expiration date Johnson & Johnson has or otherwise intends to make publicly available. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458064165 |
TOPAMAX® Strength:100 mg Package Size:60 Form:Tablet |
01/20/2020 |
19.80 |
1009.83 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458064765 |
TOPAMAX® Strength:15 mg Package Size:60 Form:Sprinkle |
01/20/2020 |
6.87 |
350.45 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458064265 |
TOPAMAX® Strength:200 mg Package Size:60 Form:Tablet |
01/20/2020 |
23.18 |
1182.26 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458064565 |
TOPAMAX® Strength:25 mg Package Size:60 Form:Sprinkle |
01/20/2020 |
8.31 |
423.65 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458063965 |
TOPAMAX® Strength:25 mg Package Size:60 Form:Tablet |
01/20/2020 |
7.27 |
370.52 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458064065 |
TOPAMAX® Strength:50 mg Package Size:60 Form:Tablet |
01/20/2020 |
14.50 |
739.47 |
None |
Innovator Multiple Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. There are no patents listed in the Orange Book for this product as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
57894064001 |
TREMFYA™ (guselkumab) prefilled syringe Strength:100mg/1mL Package Size:1 Form:1 Single syringe |
01/20/2020 |
532.11 |
11391.57 |
01/18/2031 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. This product is not listed in the Orange Book, and the patent expiration date provided is the latest projected patent expiration date Johnson & Johnson has or otherwise intends to make publicly available, and includes pending patent term extension. |
| Rx0000016 |
Janssen |
03/31/2020 |
66215061006 |
UPTRAVI® (selexipag) Strength:1000 mcg Package Size:60 Form:Tablet |
01/20/2020 |
857.42 |
18355.82 |
08/01/2030 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
06/16/2017 |
Actelion Ltd. |
None |
None |
Johnson and Johnson acquired Actelion, Ltd. on 06/16/17. As a part of Johnson and Johnson acquisition of Actelion. Ltd., Johnson and Johnson acquired this product. However, Johnson and Johnson is unable to provide the purchase price for this product since Johnson and Johnson does not have a methodology to allocate the purchase price of Actelion, Ltd. to the individual assets or products acquired from Actelion, Ltd. As a result, Johnson and Johnson has left the “Acquisition Price” field for this product blank. |
15101.00 |
None |
2015 |
14520.00 |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
66215061206 |
UPTRAVI® (selexipag) Strength:1200 mcg Package Size:60 Form:Tablet |
01/20/2020 |
857.42 |
18355.82 |
08/01/2030 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
06/16/2017 |
Actelion Ltd. |
None |
None |
Johnson and Johnson acquired Actelion, Ltd. on 06/16/17. As a part of Johnson and Johnson acquisition of Actelion. Ltd., Johnson and Johnson acquired this product. However, Johnson and Johnson is unable to provide the purchase price for this product since Johnson and Johnson does not have a methodology to allocate the purchase price of Actelion, Ltd. to the individual assets or products acquired from Actelion, Ltd. As a result, Johnson and Johnson has left the “Acquisition Price” field for this product blank. |
15101.00 |
None |
2015 |
14520.00 |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
66215061406 |
UPTRAVI® (selexipag) Strength:1400 mcg Package Size:60 Form:Tablet |
01/20/2020 |
857.42 |
18355.82 |
08/01/2030 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
06/16/2017 |
Actelion Ltd. |
None |
None |
Johnson and Johnson acquired Actelion, Ltd. on 06/16/17. As a part of Johnson and Johnson acquisition of Actelion. Ltd., Johnson and Johnson acquired this product. However, Johnson and Johnson is unable to provide the purchase price for this product since Johnson and Johnson does not have a methodology to allocate the purchase price of Actelion, Ltd. to the individual assets or products acquired from Actelion, Ltd. As a result, Johnson and Johnson has left the “Acquisition Price” field for this product blank. |
15101.00 |
None |
2015 |
14520.00 |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
66215061606 |
UPTRAVI® (selexipag) Strength:1600 mcg Package Size:60 Form:Tablet |
01/20/2020 |
857.42 |
18355.82 |
08/01/2030 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
06/16/2017 |
Actelion Ltd. |
None |
None |
Johnson and Johnson acquired Actelion, Ltd. on 06/16/17. As a part of Johnson and Johnson acquisition of Actelion. Ltd., Johnson and Johnson acquired this product. However, Johnson and Johnson is unable to provide the purchase price for this product since Johnson and Johnson does not have a methodology to allocate the purchase price of Actelion, Ltd. to the individual assets or products acquired from Actelion, Ltd. As a result, Johnson and Johnson has left the “Acquisition Price” field for this product blank. |
15101.00 |
None |
2015 |
14520.00 |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
66215060214 |
UPTRAVI® (selexipag) Strength:200 mcg Package Size:140 Form:Tablet |
01/20/2020 |
1286.46 |
27540.66 |
08/01/2030 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
06/16/2017 |
Actelion Ltd. |
None |
None |
Johnson and Johnson acquired Actelion, Ltd. on 06/16/17. As a part of Johnson and Johnson acquisition of Actelion. Ltd., Johnson and Johnson acquired this product. However, Johnson and Johnson is unable to provide the purchase price for this product since Johnson and Johnson does not have a methodology to allocate the purchase price of Actelion, Ltd. to the individual assets or products acquired from Actelion, Ltd. As a result, Johnson and Johnson has left the “Acquisition Price” field for this product blank. |
22652.00 |
None |
2015 |
21780.00 |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
66215060206 |
UPTRAVI® (selexipag) Strength:200 mcg Package Size:60 Form:Tablet |
01/20/2020 |
551.34 |
11803.14 |
08/01/2030 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
06/16/2017 |
Actelion Ltd. |
None |
None |
Johnson and Johnson acquired Actelion, Ltd. on 06/16/17. As a part of Johnson and Johnson acquisition of Actelion. Ltd., Johnson and Johnson acquired this product. However, Johnson and Johnson is unable to provide the purchase price for this product since Johnson and Johnson does not have a methodology to allocate the purchase price of Actelion, Ltd. to the individual assets or products acquired from Actelion, Ltd. As a result, Johnson and Johnson has left the “Acquisition Price” field for this product blank. |
9714.00 |
None |
2015 |
9340.00 |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
66215062820 |
UPTRAVI® (selexipag) Strength:200+800 mcg Package Size:200 Form:Tablet |
01/20/2020 |
1286.44 |
27540.44 |
08/01/2030 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
06/16/2017 |
Actelion Ltd. |
None |
None |
Johnson and Johnson acquired Actelion, Ltd. on 06/16/17. As a part of Johnson and Johnson acquisition of Actelion. Ltd., Johnson and Johnson acquired this product. However, Johnson and Johnson is unable to provide the purchase price for this product since Johnson and Johnson does not have a methodology to allocate the purchase price of Actelion, Ltd. to the individual assets or products acquired from Actelion, Ltd. As a result, Johnson and Johnson has left the “Acquisition Price” field for this product blank. |
22652.00 |
None |
2015 |
21780.00 |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
66215060406 |
UPTRAVI® (selexipag) Strength:400 mcg Package Size:60 Form:Tablet |
01/20/2020 |
857.42 |
18355.82 |
08/01/2030 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
06/16/2017 |
Actelion Ltd. |
None |
None |
Johnson and Johnson acquired Actelion, Ltd. on 06/16/17. As a part of Johnson and Johnson acquisition of Actelion. Ltd., Johnson and Johnson acquired this product. However, Johnson and Johnson is unable to provide the purchase price for this product since Johnson and Johnson does not have a methodology to allocate the purchase price of Actelion, Ltd. to the individual assets or products acquired from Actelion, Ltd. As a result, Johnson and Johnson has left the “Acquisition Price” field for this product blank. |
15101.00 |
None |
2015 |
14520.00 |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
66215060606 |
UPTRAVI® (selexipag) Strength:600 mcg Package Size:60 Form:Tablet |
01/20/2020 |
857.42 |
18355.82 |
08/01/2030 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
06/16/2017 |
Actelion Ltd. |
None |
None |
Johnson and Johnson acquired Actelion, Ltd. on 06/16/17. As a part of Johnson and Johnson acquisition of Actelion. Ltd., Johnson and Johnson acquired this product. However, Johnson and Johnson is unable to provide the purchase price for this product since Johnson and Johnson does not have a methodology to allocate the purchase price of Actelion, Ltd. to the individual assets or products acquired from Actelion, Ltd. As a result, Johnson and Johnson has left the “Acquisition Price” field for this product blank. |
15101.00 |
None |
2015 |
14520.00 |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
66215060806 |
UPTRAVI® (selexipag) Strength:800 mcg Package Size:60 Form:Tablet |
01/20/2020 |
857.42 |
18355.82 |
08/01/2030 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
06/16/2017 |
Actelion Ltd. |
None |
None |
Johnson and Johnson acquired Actelion, Ltd. on 06/16/17. As a part of Johnson and Johnson acquisition of Actelion. Ltd., Johnson and Johnson acquired this product. However, Johnson and Johnson is unable to provide the purchase price for this product since Johnson and Johnson does not have a methodology to allocate the purchase price of Actelion, Ltd. to the individual assets or products acquired from Actelion, Ltd. As a result, Johnson and Johnson has left the “Acquisition Price” field for this product blank. |
15101.00 |
None |
2015 |
14520.00 |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458058451 |
XARELTO Starter Pack™ Strength:15mg/20mg Package Size:51 Form:Tablet |
01/20/2020 |
37.32 |
798.90 |
02/17/2034 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458058010 |
XARELTO® Strength:10 mg Package Size:100 Form:Tablet |
01/20/2020 |
73.17 |
1566.46 |
02/17/2034 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458058030 |
XARELTO® Strength:10 mg Package Size:30 Form:Tablet |
01/20/2020 |
21.95 |
469.94 |
02/17/2034 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458058090 |
XARELTO® Strength:10 mg Package Size:90 Form:Tablet |
01/20/2020 |
65.85 |
1409.81 |
02/17/2034 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458057810 |
XARELTO® Strength:15 mg Package Size:100 Form:Tablet |
01/20/2020 |
73.17 |
1566.46 |
02/17/2034 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458057830 |
XARELTO® Strength:15 mg Package Size:30 Form:Tablet |
01/20/2020 |
21.95 |
469.94 |
02/17/2034 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458057890 |
XARELTO® Strength:15 mg Package Size:90 Form:Tablet |
01/20/2020 |
65.85 |
1409.81 |
02/17/2034 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458057910 |
XARELTO® Strength:20 mg Package Size:100 Form:Tablet |
01/20/2020 |
73.17 |
1566.46 |
02/17/2034 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458057930 |
XARELTO® Strength:20 mg Package Size:30 Form:Tablet |
01/20/2020 |
21.95 |
469.94 |
02/17/2034 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000016 |
Janssen |
03/31/2020 |
50458057990 |
XARELTO® Strength:20 mg Package Size:90 Form:Tablet |
01/20/2020 |
65.85 |
1409.81 |
02/17/2034 |
Single Source Drug |
None |
1 |
Many factors contribute to price increases. After we receive FDA approval, we continue to conduct research on our medicines, including studies to understand how the medicine works in real-world setting. We continue to monitor for safety and to secure regulatory approval for new indications, dosages, or improved product formulations - investments that enhance the value of our medicines for patients and society. Additional regulatory requirements, upgrading or building new manufacturing facilities, an increase in the cost of goods sold, and other market dynamics also play a role. And finally, we must continue to generate returns to invest in R&D. |
None |
Not Applicable |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
Consistent with the relevant statutes and regulations, all information contained in this report is limited to that which Johnson & Johnson believes is otherwise in the public domain or publicly available. The patent expiration date provided is the latest projected patent expiration date for patents listed in Orange Book as of March 31, 2020. |
| Rx0000008 |
Jazz Pharmaceuticals, Inc. |
03/31/2020 |
68727010001 |
Xyrem 500 MG/ML Oral Solution 180 ml |
01/08/2020 |
400.33 |
5110.12 |
09/15/2033 |
Single Source Drug |
1642525000 |
None |
None |
1 |
A change or improvement to the drug did not necessitate the price increase |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
None |
The patent expiration date contained in this report is limited to the patent information reported in the federal Food and Drug Administration’s Orange Book, as of April 30, 2019. As a result, the reported patent expiration date is limited to issued U.S. patents. Further, the reported patent expiration date does not reflect any pending patents, patent term extensions, pediatric exclusivity, or patent-related litigation, each of which is speculative and which may extend or shorten the reported expiration date.
The drug was not was acquired from another manufacturer within the last five years. |